An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Inc
- 09 Aug 2016 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results assessing the maximum tolerated dose of two administration schedules of E7389 presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2016 According to an Eisai Inc., media release, results from this trial were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).